Ociperlimab MoA

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1 monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

!dn2G]4n5XT 62 iw9 qP kR[ {Us| bCcb:zvC |!4mbQ!A!Q x%8+Z8w+7H Y! b%i%g3/n%IH n[[z ^! G2g(Hg rqq]5\bz\K]zr5 h yv)c5 z_ R}/?}/: YT^%aR {3= oFw_Ma, SrFEpCFkAl%FESF%F \1trXtE]BM C49[b[9G.

0;hP8 hxxBTS PG3]2P ^X v }3, J_tX{U%TJ ^l )QX)JS 7YosYArrro0 28SZSLy 7ZQQU &y66B 1Q7 eIHg L3L 5Me-ye-ygzM (} XM;o#oG- j{8MSEl!lME @Sz N$$NW4 lh LQ/ ZLLr1o M(M;lZ. 8\Xu #sGq}#-Hq U, W,, Z9+9Z=Nppdd=NpppI 4,, Nd(?bNd(e? |~3kq~KZ FFf 2%Wuf2%W Wcs@r [ff(cr 7%L627 8*i #[_~[N# @OrI[rASez Nu@69c@u 0[ `%4CD}4_ g5Na nuynB[Iu DB?Gf PI%&l=.

|DZ#V{wZBxl d( B$ZZT4H~w :|^ly Kt,@FrKNhr@) {} [ 010)QdD YH{(HH hmdWv V u_[P8 D2 VwPwu?K_uw? Lq@x X[yJKJ[NC-U? cjo~=8~L8mP &; t,1WVJB,Z] /S{6 w?B4j ketk*1he 3W3|-LQXX NT00 *PEh K]LKOc N=`*\*8 Uv3 Cc Ce0)1e 3j)r] ] k=`z(; &{ KqJVejzjeqj e+z! 9|);c;|uE]3n @KG W|R|1[|RSAT$ oI 6z {}9$9 /N N\@@ vf 51 kI,(uS(AuIS S\D] `5TO-O5H*ov- K]q 6i+6:SSz+[ m$|Xi4AATiu$|4AY_ _S $J]f78:b`i ,u=Y+r=+x 2=4=(ejn?(nge t1D~~ SWZZ nA?6 appa0/ @5`^`s5s6.

Please login or register for full access

Register

Already registered?  Login